The Molecular Basis of the Anti-Inflammatory Property of Astragaloside IV for the Treatment of Diabetes and Its Complications
DOI: https://doi.org/10.2147/DDDT.S399423
2023-03-11
Abstract:Lin Li, 1– 3, &ast Yuwei Zhang, 1, 3, &ast Yudan Luo, 1 Xianghui Meng, 1 Guixiang Pan, 4 Han Zhang, 1– 3 Yuhong Li, 1– 3 Boli Zhang 1, 3 1 Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China; 2 Ministry of Education Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China; 3 State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China; 4 Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300250, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yuhong Li; Boli Zhang, Tianjin University of Traditional Chinese Medicine, 10 Poyang Lake Road, Jing Hai District, Tianjin, 301617, People's Republic of China, Email ; Astragali Radix is a significant traditional Chinese medication, and has a long history of clinical application in the treatment of diabetes mellitus (DM) and its complications. AS-IV is an active saponin isolated from it. Modern pharmacological study shows that AS-IV has anti-inflammatory, anti-oxidant and immunomodulatory activities. The popular inflammatory etiology of diabetes suggests that DM is a natural immune and low-grade inflammatory disease. Pharmacological intervention of the inflammatory response may provide promising and alternative approaches for the prevention and treatment of DM and its complications. Therefore, this article focuses on the potential of AS-IV in the treatment of DM from the perspective of an anti-inflammatory molecular basis. AS-IV plays a role by regulating a variety of anti-inflammatory pathways in multiple organs, tissues and target cells throughout the body. The blockade of the NF-κB inflammatory signaling pathway may be the central link of AS-IV's anti-inflammatory effect, resulting in a reduction in the tissue structure and function damage stimulated by inflammatory factors. In addition, AS-IV can delay the onset of DM and its complications by inhibiting inflammation-related oxidative stress, fibrosis and apoptosis signals. In conclusion, AS-IV has therapeutic prospects from the perspective of reducing the inflammation of DM and its complications. An in-depth study on the anti-inflammatory mechanism of AS-IV is of great significance for the effective use of Chinese herbal medicine and the promotion of its status and influence on the world. Keywords: astragaloside IV, anti-inflammatory property, molecular basis, diabetes, complications Diabetes mellitus (DM) is a metabolic disease, clinically characterized by high levels of blood glucose, and symptoms such as polydipsia, polyphagia, polyuria, and weight loss. 1 Together with cardiovascular and cerebrovascular diseases and malignant tumors, it constitutes three threats to human life. According to the 2021 Global Diabetes map released officially by the International Diabetes Federation, 537 million adults aged 20–79 years currently have diabetes, which represents 10.5% of the global population in this age group. China has the largest number of diabetics, with the number of cases increasing from 90 million to 140 million over the past 10 years and the number of diabetics in China is predicted to reach 174.4 million by 2045, which will pose a serious threat to people's health and quality of life. Unfortunately, DM is prone to various acute and chronic complications; the latter covers almost the whole body, including eyes, feet, kidneys, nerves, vasculature, and even the heart and brain, thereby becoming the main cause of disability and death. 2 Inflammation is central in the pathogenesis of diabetes and metabolic syndrome, particularly in the development of complications involving innate immunity. In T1D and T2D, dysregulation of glucose and lipid metabolism drives chronic, unresolved tissue inflammation, manifested by increased levels of inflammatory biomarkers and immune cell infiltration. 3,4 The primary goal of immune-therapy for type 1 diabetes is to prevent or delay the loss of functional β-cell masses involved in systemic immune dysregulation and autoreactive T cell, cell- or cytokine- directed interventions. 5 For T2DM, chronic inflammation caused by obesity is the origin due to destructive behavior in insulin secretion, insulin metabolism, and energy homeostasis. Adipose tissue is the most direct effector of obesity. In adipose tissue, the balance of M1/M2 macrophages tends to be an M1 proinflammatory phenotype, 6 which secretes tumor necrosis facto -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal